X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs BIOCON - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA BIOCON SUN PHARMA/
BIOCON
 
P/E (TTM) x 28.8 16.8 171.7% View Chart
P/BV x 2.5 2.6 95.8% View Chart
Dividend Yield % 0.6 0.4 144.0%  

Financials

 SUN PHARMA   BIOCON
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
BIOCON
Mar-18
SUN PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs6791,188 57.1%   
Low Rs375305 123.1%   
Sales per share (Unadj.) Rs121.168.7 176.3%  
Earnings per share (Unadj.) Rs13.47.6 177.1%  
Cash flow per share (Unadj.) Rs20.714.0 148.1%  
Dividends per share (Unadj.) Rs2.751.00 275.0%  
Dividend yield (eoy) %0.50.1 389.5%  
Book value per share (Unadj.) Rs172.686.3 199.9%  
Shares outstanding (eoy) m2,399.26600.00 399.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.410.9 40.1%   
Avg P/E ratio x39.498.9 39.9%  
P/CF ratio (eoy) x25.553.4 47.7%  
Price / Book Value ratio x3.18.6 35.3%  
Dividend payout %20.613.2 155.3%   
Avg Mkt Cap Rs m1,264,650447,900 282.4%   
No. of employees `00017.56.1 284.6%   
Total wages/salary Rs m59,6719,311 640.9%   
Avg. sales/employee Rs Th16,608.16,705.8 247.7%   
Avg. wages/employee Rs Th3,409.61,514.2 225.2%   
Avg. net profit/employee Rs Th1,833.8736.9 248.9%   
INCOME DATA
Net Sales Rs m290,65941,234 704.9%  
Other income Rs m10,2552,062 497.3%   
Total revenues Rs m300,91443,296 695.0%   
Gross profit Rs m63,0768,291 760.8%  
Depreciation Rs m17,5333,851 455.3%   
Interest Rs m5,553615 902.8%   
Profit before tax Rs m50,2465,887 853.5%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0091,569 383.0%   
Profit after tax Rs m32,0934,531 708.3%  
Gross profit margin %21.720.1 107.9%  
Effective tax rate %12.026.7 44.9%   
Net profit margin %11.011.0 100.5%  
BALANCE SHEET DATA
Current assets Rs m310,69241,486 748.9%   
Current liabilities Rs m173,39621,413 809.8%   
Net working cap to sales %47.248.7 97.0%  
Current ratio x1.81.9 92.5%  
Inventory Days Days9964 154.8%  
Debtors Days Days11294 118.5%  
Net fixed assets Rs m232,47750,661 458.9%   
Share capital Rs m2,3993,000 80.0%   
"Free" reserves Rs m411,69148,808 843.5%   
Net worth Rs m414,09151,808 799.3%   
Long term debt Rs m15,22617,898 85.1%   
Total assets Rs m646,93899,897 647.6%  
Interest coverage x10.010.6 95.1%   
Debt to equity ratio x00.3 10.6%  
Sales to assets ratio x0.40.4 108.8%   
Return on assets %5.85.2 113.0%  
Return on equity %7.88.7 88.6%  
Return on capital %10.29.6 105.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02512,058 547.6%   
Fx outflow Rs m38,6107,348 525.5%   
Net fx Rs m27,4154,710 582.1%   
CASH FLOW
From Operations Rs m21,9656,621 331.7%  
From Investments Rs m-6,813-6,840 99.6%  
From Financial Activity Rs m-27,305-2,397 1,139.1%  
Net Cashflow Rs m-8,442-2,612 323.2%  

Share Holding

Indian Promoters % 63.7 40.4 157.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 5.1 8.4 61.1%  
FIIs % 23.0 10.7 215.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 19.9 41.7%  
Shareholders   133,026 109,995 120.9%  
Pledged promoter(s) holding % 0.5 0.0 1,325.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 23, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS